Your browser doesn't support javascript.
loading
Sex differences in presentation of atrial fibrillation: Findings from 30-day ambulatory monitoring in real-world practice.
Tan, Jian Liang; Johnson, Linda; Dziubinski, Marek; Napiorkowski, Natan; Witkowska, Olga; Slusarczyk, Magdalena E; Healey, Jeff S; Russo, Andrea M.
Afiliação
  • Tan JL; Cardiovascular Division, Cooper University Health System, Cooper Medical School of Rowan University, United States of America.
  • Johnson L; Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
  • Dziubinski M; Medicalgorithmics S. A., Warsaw, Poland.
  • Napiorkowski N; Medicalgorithmics S. A., Warsaw, Poland.
  • Witkowska O; Medicalgorithmics S. A., Warsaw, Poland.
  • Slusarczyk ME; Medicalgorithmics S. A., Warsaw, Poland.
  • Healey JS; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
  • Russo AM; Cardiovascular Division, Cooper University Health System, Cooper Medical School of Rowan University, United States of America.
Am Heart J Plus ; 22: 100208, 2022 Oct.
Article em En | MEDLINE | ID: mdl-38558904
ABSTRACT

Background:

Women are less likely to receive oral anticoagulation or ablation for treatment of atrial fibrillation (AF). Identification of sex differences in arrhythmia characteristics and symptoms may lead to a better understanding of potential reasons for these differences.

Objectives:

To determine sex differences in AF with respect to heart rate, duration, burden, and symptoms in patients undergoing mobile cardiac telemetry (MCT) monitoring.

Methods:

All patients who registered for ≤30-day MCT using PocketECG (MediLynx) in the USA in 2017 were included (n = 27,512, 58 % women). PocketECG records and transmits a three-lead ambulatory electrocardiogram (ECG) with real-time beat-to-beat analysis. Sex-related differences were analyzed with Chi2 and Spearmans rho.

Results:

Fewer women than men were diagnosed with AF lasting ≥30s (13.7 % versus [vs] 19.0 %, p < 0.001). AF burden was lower in women in all age groups <90 years (all p < 0.01). Women were older at the time of AF diagnosis (median 76 vs 73 years, p < 0.001), had faster heart rate during AF (mean 104.7 ± 26.0 vs 96.7 ± 26.7 bpm, p < 0.001), and shorter AF duration (mean 96.2 ± 176.0 vs 121.6 ± 189.9 min, p < 0.001). There was a non-significant trend toward more symptoms (such as dizziness, racing heart, fatigue, or palpitations) during AF in women compared to men (46.5 % vs 43.7 %, p = 0.062).

Conclusions:

AF was less prevalent and occurred at lower burdens in women than men in each age strata. Despite faster heart rates in AF in women, there were no significant sex differences in reported symptoms during AF. Sex differences in therapy cannot be explained by differences in symptoms or rates in AF. Condensed abstract Real-world data on sex differences in AF using a 30-day MCT monitoring device remain scarce. We aim to determine the sex differences in AF with respect to prevalence, burden, heart rate, and symptom in patients undergoing ≤30-day MCT monitoring. Our data analysis suggests that fewer women than men had AF, women were older at diagnosis of AF, and women with AF had higher mean heart rate, shorter mean AF duration, and lower mean AF burden than men. Further studies are needed to examine reasons for sex differences, specifically in relation to AF therapy and its impact on clinical outcomes.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am Heart J Plus Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Am Heart J Plus Ano de publicação: 2022 Tipo de documento: Article